The collaboration will explore combining TransCode's proprietary TTX delivery platform with Debiopharm's expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode Therapeutics Collaborates With Debiopharm; Financial Terms Not Disclosed
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.